Selecting the optimal in vivo platform is critical for generating translatable oncology data. BioLegacy provides deep expertise across an extensive range of solid tumor models, from standard ectopic xenografts to complex orthotopic implantations that replicate the native tumor microenvironment. Our models include syngeneic models for immuno-oncology, humanized mice for evaluating biologics, and specialized assays like the hollow fiber model for early efficacy assessment, ensuring your therapeutic is tested in the most scientifically relevant system.
Modeling systemic hematological malignancies requires robust, disseminated disease models and a deep understanding of disease progression. At BioLegacy, we provide definitive efficacy data for your anti-leukemia therapeutic by leveraging well-characterized models to accurately recapitulate human disease. Our expertise in tracking tumor burden in the bone marrow, spleen, and peripheral blood delivers a clear, quantitative assessment of your compound’s therapeutic activity against disseminated cancer.
Targeting metastatic disease, the primary cause of cancer mortality, requires preclinical models that can effectively recapitulate the process of tumor cell dissemination and colonization. We utilize robust, induced metastasis models designed to specifically assess your compound’s ability to inhibit these critical steps in cancer progression. Leveraging well-characterized platforms, such as the B16-F10 lung metastasis model, we deliver definitive, quantitative data on the formation of metastatic nodules in distant organs, providing clear insights into your therapeutic’s anti-metastatic potential.
Developing effective therapeutics for glioblastoma requires overcoming the immense challenge of the blood-brain barrier and accurately modeling the unique, infiltrative nature of this aggressive disease. BioLegacy uses advanced orthotopic xenograft models, implanting human GBM cell lines directly into the brain to create a clinically relevant tumor microenvironment. Our expertise in stereotactic neurosurgery, combined with longitudinal monitoring of tumor burden via bioluminescent imaging and survival analysis as a primary endpoint, provides the definitive efficacy data needed to de-risk your CNS-penetrant compound and confidently advance your neuro-oncology program.
